Table 2.
LT4 dose (µg) | Percentage of each LT4 dose prescribed per year |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
||||||||||
No hypo | Hypo | No hypo | Hypo | No hypo | Hypo | No hypo | Hypo | No hypo | Hypo | No hypo | Hypo | No hypo | Hypo | No hypo | Hypo | No hypo | Hypo | |
25 | 6.8 | 5.7 | 7.3 | 5.8 | 7.3 | 6.2 | 8.1 | 7.5 | 8.1 | 8.1 | 9.0 | 8.4 | 8.5 | 8.5 | 8.5 | 8.5 | 8.2 | 8.4 |
50 | 15.6 | 14.2 | 15.1 | 14.1 | 15.0 | 14.9 | 15.4 | 15.7 | 16.0 | 16.8 | 16.7 | 16.9 | 15.7 | 16.8 | 15.6 | 17.1 | 15.5 | 16.9 |
75 | 14.8 | 14.5 | 14.0 | 13.4 | 14.6 | 13.8 | 15.0 | 13.8 | 14.7 | 14.5 | 15.2 | 14.5 | 15.9 | 14.8 | 15.4 | 15.1 | 15.7 | 15.4 |
88 | 7.7 | 6.3 | 7.2 | 7.3 | 8.2 | 7.2 | 8.2 | 7.8 | 9.2 | 8.0 | 9.1 | 8.3 | 9.1 | 8.5 | 9.4 | 8.4 | 9.7 | 9.0 |
100 | 16.2 | 15.6 | 15.8 | 15.5 | 15.3 | 14.1 | 16.2 | 13.6 | 14.9 | 13.7 | 14.7 | 13.8 | 14.9 | 14.1 | 14.7 | 14.1 | 15.1 | 14.0 |
112 | 8.3 | 7.8 | 8.7 | 8.3 | 8.8 | 8.4 | 9.0 | 8.3 | 8.1 | 7.9 | 8.2 | 8.1 | 8.7 | 7.9 | 8.8 | 7.7 | 9.0 | 8.3 |
125 | 10.1 | 11.2 | 11.0 | 10.8 | 11.1 | 10.3 | 9.1 | 10.3 | 10.0 | 9.9 | 9.3 | 9.6 | 9.4 | 9.4 | 9.1 | 9.3 | 9.0 | 9.0 |
137 | 3.6 | 5.0 | 4.3 | 5.5 | 4.4 | 5.4 | 4.4 | 5.1 | 4.7 | 4.7 | 4.2 | 4.5 | 4.2 | 4.7 | 4.8 | 4.8 | 4.7 | 4.6 |
150 | 8.7 | 9.0 | 8.1 | 8.9 | 7.2 | 9.1 | 7.3 | 8.1 | 7.0 | 7.5 | 6.7 | 7.1 | 6.8 | 6.8 | 6.4 | 7.0 | 6.4 | 6.7 |
175 | 4.1 | 5.5 | 4.1 | 5.1 | 4.6 | 5.3 | 4.1 | 5.0 | 4.1 | 4.5 | 4.2 | 4.7 | 4.0 | 4.7 | 4.4 | 4.3 | 4.2 | 4.2 |
200 | 3.7 | 4.8 | 3.9 | 4.6 | 3.2 | 4.9 | 2.9 | 4.3 | 2.8 | 3.9 | 2.6 | 3.8 | 2.6 | 3.6 | 2.7 | 3.5 | 2.5 | 3.2 |
300 | 0.3 | 0.4 | 0.3 | 0.6 | 0.3 | 0.5 | 0.3 | 0.4 | 0.3 | 0.3 | 0.2 | 0.3 | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 0.3 |
Gray shading indicates the most frequently prescribed doses.
LT4, levothyroxine